Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Cancer. 2016 Aug 10;122(21):3336–3343. doi: 10.1002/cncr.30197

Table 3.

Survival endpoints in matched cohort.

Dasatinib Nilotinib P value
Survival at 3 years (%)
OS 99 93 0.95
EFS 89 87 0.99
TFS 95 89 0.28
FFS 74 63 0.71

NOTE: OS, overall survival; EFS, event free survival; FFS, failure free survival; TFS, transformation free survival.